This company has been marked as potentially delisted and may not be actively trading. Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock APLS Analyst Ratings Over TimeTypeCurrent Forecast7/27/25 to 7/27/261 Month Ago6/27/25 to 6/27/263 Months Ago4/28/25 to 4/28/261 Year Ago7/27/24 to 7/27/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)3 Buy rating(s)11 Buy rating(s)Hold17 Hold rating(s)18 Hold rating(s)18 Hold rating(s)9 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)2 Sell rating(s)0 Sell rating(s)Consensus Price Target$36.29$35.72$34.89$40.00Forecasted Upside-11.54% Downside-12.94% Downside-14.87% Downside104.19% UpsideConsensus RatingHoldHoldHoldModerate Buy APLS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History APLS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Apellis Pharmaceuticals Stock vs. The CompetitionTypeApellis PharmaceuticalsMedical CompaniesBroader MarketConsensus Rating Score 2.10 2.29 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside-11.54% Downside963.47% Upside13.46% UpsideNews Sentiment RatingNeutral NewsSee Recent APLS NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/15/2026 Cantor Fitzgerald5 of 5 starsSteve SeedhouseNot RatedReiterated RatingNeutral5/8/2026 Weiss Ratings5 of 5 stars UpgradeSell (D) ➝ Hold (C-)4/17/2026 Wells Fargo & Company3 of 5 starsDerek Archila4 of 5 starsDowngradeOverweight ➝ Equal Weight$26.00 ➝ $41.00+0.32%4/2/2026 Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAdam WalshSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/2/2026 MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGraig SuvannavejhSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$20.00 ➝ $41.00+1.51%4/1/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAnupam RamaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$37.00 ➝ $41.00+1.52%4/1/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEliana MerleSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$24.00 ➝ $41.00+1.50%4/1/2026 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRyan DeschnerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold4/1/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYigal NochomovitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$44.00 ➝ $41.00+1.50%4/1/2026 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDouglas TsaoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$48.00 ➝ $41.00+1.91%Buy this stock today (Ad)Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.Get the name, ticker, and full Hotlist before markets open3/31/2026 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold3/31/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold3/31/2026 Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold3/31/2026 Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph StringerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold2/25/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLisa WalterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetSector Perform$22.00 ➝ $21.00-0.73%2/25/2026 WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLaura ChicoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$20.00 ➝ $18.00-18.66%1/21/2026 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTazeen AhmadSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeNeutral ➝ Buy$28.00+36.79%1/12/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSalveen RichterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSell$19.00-18.09%12/19/2025 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAnnabel SamimySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$55.00 ➝ $48.00+94.33%11/6/2025 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndy ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoveragePeer Perform10/31/2025 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPhil NadeauSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$50.00 ➝ $45.00+113.98%7/2/2025 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJudah FrommerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$25.00 ➝ $26.00+42.46%5/8/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGreg HarrisonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetSector Perform$28.00 ➝ $20.00+14.35%11/6/2024 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBiren AminSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$40.00 ➝ $32.00+13.98%11/6/2024 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOutperform$65.00 ➝ $40.00+42.48%10/31/2024 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingU. RaffatSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy8/9/2024 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$85.00 ➝ $83.00+119.34%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:29 PM ET. APLS Forecast - Frequently Asked Questions What is Apellis Pharmaceuticals' forecast for 2026? According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Apellis Pharmaceuticals is $36.29, with a high forecast of $52.00 and a low forecast of $18.00. Should I buy or sell Apellis Pharmaceuticals stock right now? 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There is currently 1 sell rating, 17 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" APLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APLS, but not buy additional shares or sell existing shares. Does Apellis Pharmaceuticals's stock price have much downside? According to analysts, Apellis Pharmaceuticals's stock has a predicted downside of -11.54% based on their 12-month stock forecasts. Has Apellis Pharmaceuticals been upgraded by Wall Street analysts recently? Over the previous 90 days, Apellis Pharmaceuticals's stock had 1 upgrade by analysts. What analysts cover Apellis Pharmaceuticals? Apellis Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors? Analysts like Apellis Pharmaceuticals less than other "medical" companies. The consensus rating score for Apellis Pharmaceuticals is 2.10 while the average consensus rating score for "medical" companies is 2.29. Learn more on how APLS compares to other companies. Stock Forecasts and Research Tools Related Companies VTRS Stock Forecast GMAB Stock Forecast ASND Stock Forecast BBIO Stock Forecast ELAN Stock Forecast ABVX Stock Forecast AXSM Stock Forecast SMMT Stock Forecast RDY Stock Forecast ARWR Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Apellis Pharmaceuticals RecommendationsWall Street ZenCantor FitzgeraldWeiss RatingsWells Fargo & CompanyMizuhoRoth CapitalCitigroupJPMorgan Chase & Co.HC WainwrightBarclaysRaymond James FinancialRobert W. BairdNeedham & Company LLCWilliam BlairJefferies Financial Group This page (NASDAQ:APLS) was last updated on 7/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get started with MarketBeat. — Hello!Make the most of your MarketBeat account.37% completed. Great work!View a Company's Profile PageView Our Financial CalendarsView Today's Analyst RatingsRead Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant Alert Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
